

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



COMMON SPLENDOR INTERNATIONAL HEALTH INDUSTRY GROUP LIMITED

(Incorporated in Bermuda with limited liability)

(Stock Code: 286)

VOLUNTARY ANNOUNCEMENT ESTABLISHMENT OF CHINA HEADQUARTER AND COMMON SPLENDOR HEALTH MANAGEMENT SHENZHEN CHAIN CENTRE BY THE GROUP

ESTABLISHMENT OF HEALTH MANAGEMENT CHAIN CENTRE IN SHENZHEN

On 30 November 2015, Guangzhou Common Splendor Medical Technology Co., Ltd.* (廣州同佳醫療科技有限公司), a wholly-owned subsidiary of Common Splendor International Health Management Limited, entered into a Shenzhen City Real Estate Tenancy Agreement* (深圳市房屋租賃合同書) (“**Tenancy Agreement**”) with Shenzhen Shenlong Yida Science and Technology Park Development Co., Ltd.* (深圳市深龍億達科技園發展有限公司), an independent third party, for the purpose of establishing the China headquarter of the Group and a Common Splendor Health Management Shenzhen Centre. The first operational centre of Common Splendor Health Management, the Guangzhou Centre, was put into operation in 2014 and has recorded satisfactory business performance since then as well as accomplishing a standardized management and a management team. The Shenzhen Centre is the second centre of the chain expansion. Apart from the Shenzhen Centre, the Group will continue to identify suitable cities to develop its health management chain centres.

THE TENANCY AGREEMENT

Pursuant to the Tenancy Agreement, the Group would lease a premise with an area of 1,943 square meters at Zone A, 4th Floor, Complex Building, 99 Qiaocheng East Road, Nanshan District, Shenzhen at a monthly rent of approximately RMB230,000 for a term of two years and nine months renewable upon expiration, for the purpose of establishing a Common Splendor Health Management Shenzhen Centre. The period of the Tenancy Agreement is up to 31 August 2018. Upon expiration of the lease, the Group has the preemptive right to lease the premise.

BUSINESS OF COMMON SPLENDOR HEALTH MANAGEMENT

As disclosed in the 2014 annual report of the Group, on 16 October 2013, the Group rented a two-floor commercial building with approximately 2,975 square meters in Guangzhou Biological Island as its health management business headquarter and the first operational centre.

Current principal businesses of Common Splendor Health Management include health management and cutting-edge medical therapies. The health management services include all-around health management and anti-aging management, sub-health management, tumour management, cardiovascular management and diabetes management, and the cutting-edge medical therapies include hemopurification, metabolism therapy, cell therapy and gene therapy. The profit before tax of Common Splendor Health Management for 2014 was approximately HKD18,198,000, and approximately HKD6,419,000 for the first half of 2015.

BUSINESS PARTNERS OF AND OUTLOOK FOR COMMON SPLENDOR HEALTH MANAGEMENT

In 2013, a strategic cooperation agreement was entered into by eight institutions, including American Anti-aging Alliance, AMAbiotics International Limited of France, DaAn Gene Co., Ltd of Sun Yat-sen University (中山大學達安基因股份有限公司), China-Hong Kong Society for Medical and Health Care* (中國香港醫療衛生學會), and Dongguan Southern Medical University Metabolic Medicines Research and Development Company Limited* (東莞南方醫大代謝醫學研發有限公司) with an aim to tap into the domestic health industry. Currently, American Anti-aging Alliance and AMAbiotics International Limited of France have become the shareholders of Jumbo Glory Investment Limited, a subsidiary of the Group which jointly invested in Guangzhou Common Splendor Medical Technology Limited* (廣州同佳醫療科技有限公司). DaAn Gene Co., Ltd of Sun Yat-sen University and Dongguan Southern Medical University Metabolic Medicines Research and Development Company Limited* (東莞南方醫大代謝醫學研發有限公司) have also invested in Guangzhou Common Splendor Medical Technology Limited* (廣州同佳醫療科技有限公司) through their joint investments in Guangzhou Common Splendor Health Industry Investment Centre* (廣州同佳健康產業投資中心).

The Group has formulated its strategy, an emphasis of which is placed on whole life-cycle health services and cutting-edge medical therapies that cover the healthcare industry chain of healthcare-related equipment, pharmaceuticals, foodstuff products, lifestyle, culture and education. Further disclosure will be made to update the investors of the development on a timely basis.

By order of the Board
**Common Splendor International
Health Industry Group Limited**
Cheung Wai Kuen
Chairman

Hong Kong, 30 November 2015

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Cheung Wai Kuen and Mr. Cheng Hau Yan as executive Directors; Mr. Lin Jiang as non-executive Director; and Mr. Mai Yang Guang, Mr. Yau Chi Ming and Mr. Huang Liang as independent non-executive Directors.

* *For identification purposes only*